<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007653</url>
  </required_header>
  <id_info>
    <org_study_id>HOKUSAI post VTE study</org_study_id>
    <nct_id>NCT04007653</nct_id>
  </id_info>
  <brief_title>Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE</brief_title>
  <acronym>HOKUSAIpostVTE</acronym>
  <official_title>Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HOKUSAI post VTE study contains of two different research questions; one on the long term
      outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post
      thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH)
      respectively. Our aim of the study is to compare the long term outcomes along with the
      quality of life assessment of VTE in a group treated with heparin+VKA versus a group treated
      with heparin+edoxaban in the acute setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post thrombotic syndrome (PTS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>PTS according to Villalta</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic thromboembolic pulmonary hypertension (CTEPH)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>according to clinical and objective criteria</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Venous Thromboembolic Disease</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Patients treated with heparin+edoxaban for VTE</arm_group_label>
    <description>Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with heparin+VKA for VTE</arm_group_label>
    <description>Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Patients treated with heparin+VKA for VTE</arm_group_label>
    <arm_group_label>Patients treated with heparin+edoxaban for VTE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were included in the HOKUSAI VTE trial for treatment of their DVT or PE.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant in the HOKUSAI VTE trial

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ingrid Bistervels, MD</last_name>
    <phone>+31205665976</phone>
    <email>i.m.bistervels@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roisin Bavalia, MD</last_name>
    <phone>0031 205667516</phone>
    <email>r.bavalia@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>S. Middeldorp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Post thrombotic syndrome</keyword>
  <keyword>Edoxaban</keyword>
  <keyword>Vitamin K antagonist</keyword>
  <keyword>Chronic Thromboembolic Pulmonary Hypertension</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

